🇪🇺 Adjuvant letrozole (postmenopausal women) in European Union

Adjuvant letrozole (postmenopausal women) (adjuvant-letrozole-postmenopausal-women) regulatory status in European Union.

Marketing authorisation

EMA

  • Status: approved

Adjuvant letrozole (postmenopausal women) in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is Adjuvant letrozole (postmenopausal women) approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for Adjuvant letrozole (postmenopausal women) in European Union?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.